Severe COVID-19 Reactivates Dormant Viruses, Linked to Long COVID Symptoms

A recent study highlights that experiencing severe COVID-19 can lead to the reactivation of dormant viruses in the body, even among individuals with otherwise healthy immune systems. Key viruses identified include Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), and anelloviruses. Although these latter viruses are commonly present without proving harmful, their reactivation has been associated with persistent disabilities seen in long COVID cases, according to research published on August 5 in the journal Nature.

Anna Cliffe, an associate professor of microbiology, immunology, and cancer biology at the University of Virginia, praised this analysis as a significant contribution to the field, calling it "one of the largest and most carefully done studies" in examining such phenomena. She remarked that the activation of dormant viruses could complicate the inflammatory response associated with COVID-19 itself.

Dr. Esther Melamed, a neuroimmunologist at the University of Texas at Austin and co-author of the study, emphasized the implications of these findings, suggesting a pressing need for further investigation into these viruses and the potential design of antiviral treatments specifically for them.

Understanding Viral Reactivation

The research tracked 1,154 adults hospitalized with COVID-19 of varying severity over the course of a year. Blood samples, nasal swabs, and lung fluids were collected at multiple intervals: during the first month of illness and at three, six, nine, and twelve months post-infection. Through these tests, researchers sought to identify viral RNA, a genetic marker indicating viral reactivation during and after the infection by SARS-CoV-2, the virus behind COVID-19.

Findings revealed that a notable number of dormant viruses became active amidst the acute infection phase, particularly the herpes family viruses. The reactivation process varied, with EBV and anelloviruses surfacing early and CMV and HSV activating later on. Each reactivated virus correlated with distinct immune responses and clinical outcomes among the patients.

About half of the participants—550 out of 1,148—exhibited reactivation of at least one virus, shedding light on a surprising pattern that arose even in individuals with intact immune defenses. However, a subset of these patients developed debilitating long COVID symptoms, such as fatigue and difficulty performing routine activities. Notably, those with anellovirus activity post-acute infection experienced worse outcomes.

Cliffe acknowledged the study's rigorous methodology, pointing to the longitudinal follow-up and the replication of results across different patient cohorts using Mount Sinai biobank samples.

Mechanisms Behind Viral Reactivation

The phenomenon of herpesviruses reactivating in previously healthy individuals is not unprecedented. Cliffe noted that research involving astronauts and Antarctic explorers—individuals who undergo rigorous health screenings—demonstrates similar patterns during intense psychological or physical stress. This suggests a potential vulnerability that severe health challenges, like COVID-19, may expose.

Dr. Melamed theorizes that significant bodily stressors can compromise the immune system's ability to keep these dormant viruses in check. As the immune system reallocates its resources in response to severe stress—whether from an infection or another health crisis—the dormant viruses can "wake up" and become active.

Cliffe also pointed to how inflammatory signals associated with illness might play a direct role in viral reactivation. For example, her research has indicated that molecules like IL-1 and IL-6—both involved in immune signaling—can trigger the activation of dormant herpes viruses within neurons, providing a pathway for their resurgence during illnesses.

While the study did find viral RNA, a measure indicating that these viruses are undergoing transcription, Cliffe notes that this doesn't definitively demonstrate the presence of infectious viral particles. The authors of the study tackled this by showing the presence of both viral RNA and antibodies as well as increased immune responses associated with the viruses.

However, a critical caveat remains: the study establishes a correlation between viral reactivation and adverse clinical outcomes, but this doesn't equate to a proven causal relationship. Future research must focus on interventional studies to evaluate whether antiviral medications targeting these viruses can improve patient outcomes both in cases of severe COVID-19 and in managing long COVID symptoms.

This information serves educational purposes and is not intended as medical guidance.